CD274 and non-small cell lung carcinoma: In this context, our study could provide the first proof-of-concept that serum cEV miRNAs, in a cohort of advanced stage NSCLC patients with high PD-L1 expression, could be new biomarkers for NSCLC diagnosis, for pembrolizumab response prediction, for both PFS and OS prognosis and for metastases investigation (Figure 7).